Can-Fite BioPharma
About Science Pipeline Investor Information Contact Us

Investor Information

Investor Information

Profile

Business Description

Can-Fite BioPharma Ltd. is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2017 for two indications, rheumatoid arthritis and psoriasis. The rheumatoid arthritis Phase III protocol has recently been agreed with the European Medicines Agency. Can-Fite's liver cancer drug Namodenoson is in Phase II trials for patients with liver cancer and is slated to enter Phase II for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for hepatocellular carcinoma by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and is being prepared for an IND submission to the FDA and a Phase I trial. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.

Address:
10 Bareket Street, Kiryat Matalon
P.O. Box 7537
Petah-Tikva, 49170

Website:
http://www.canfite.com/

Email:
info@canfite.co.il

Telephone:
+972-3-9241114
(800) 716-4880

Fax:
+972-3-9249378

Details

CEO:
Pnina Fishman, Ph.D.

Issue Type:
On the NYSE U.S. ADRs are traded at a ratio of 1 ADR = 2 common shares

Auditors:
Ernst & Young Israel

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

Sub-Industry:
Biotechnology

NAICS:
541711

SIC:
2834